Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.34% | 38.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.37% | -14.91% | |||
| Operating Income | 38.37% | 14.91% | |||
| Income Before Tax | 13.80% | 13.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.77% | 13.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.77% | 13.38% | |||
| EBIT | 38.37% | 14.91% | |||
| EBITDA | 38.78% | 15.05% | |||
| EPS Basic | 13.80% | 13.40% | |||
| Normalized Basic EPS | 38.38% | 14.47% | |||
| EPS Diluted | 15.08% | 12.09% | |||
| Normalized Diluted EPS | 38.38% | 14.47% | |||
| Average Basic Shares Outstanding | 0.03% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||